Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
2 hedge funds and large institutions have $0 invested in Synergy Pharmaceuticals, Inc Common Stock in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 9 closing their positions.
83% less funds holding
Funds holding: 12 → 2 (-10)
89% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 9
100% less capital invested
Capital invested by funds: $1K → $0 (-$1K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
SGYP Hedge Fund Activity: Q2 2019 in Review
2 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q2 2019, worth a combined $0 — down 100% from $1K a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of SGYP and 1 opened new positions — a net loss of 8 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $1K sold.
- 2 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q2 2019, down from 12 in Q1 2019.
- Funds reported $0 of Synergy Pharmaceuticals, Inc Common Stock stock for Q2 2019, down 100% quarter-over-quarter.
- 1 fund opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q2 2019 and 9 closed out, a net change of -8 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q2 2019 was Tower Research Capital (TRC), an estimated $1K sold.
Based on aggregated 13F filings for Q2 2019.